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Summary
Measurement is fundamental to science. In medicine measurement underpins most clinical decisions. Outcome measures for rheumatoid
arthritis clinical trials (OMERACT) is an informal collaborative group of professionals dedicated to improving outcome measurement in the
rheumatic disease. The methodologic hallmark of the OMERACT process is captured in the OMERACT ﬁlter e truth, discrimination, and
feasibility. Using the key elements of the OMERACT ﬁlter a comprehensive checklist for evaluating reported measures is provided. The check-
list guides the potential user through a series of questions. The checklist is also an important resource for researchers working in the ﬁeld of
measurement.
ª 2006 Published by Elsevier Ltd on behalf of OsteoArthritis Research Society International.




SocietyOutcome measures for rheumatoid arthritis clinical trials
(OMERACT) is an informal collaborative group of profes-
sionals dedicated to improving outcome measurement in
the rheumatic disease1 (www.omeract.org). The OMERACT
process is data-driven, iterative and consensus building.
It aims to examine existing measures and explore new
measures in order to make selection of outcome measures
explicit and justiﬁable. Where consensus does not or
cannot be reached, OMERACT formulates appropriate
research agenda. Its recent work in developing an magnetic
resonance imaging (MRI) score of disease activity and
damage in rheumatoid arthritis (RA) is an example2. The
methodologic hallmark of this process is captured in the
OMERACT ﬁlter e truth, discrimination, and feasibility3.
What follows is an explanation of these three components
of the ﬁlter to provide guidance to assessing past work
and designing future investigations in the development
and validation of measures of structural outcome in osteoar-
thritis. This introduction will also brieﬂy describe how the
historical development of measurement in the medical sci-
ences, adopted from conventions arising from either psy-
chology4 or the natural sciences5 has led to a non-
intuitive, ambiguous nomenclature that can confuse the
clinical research process and its application. The OMER-
ACT process encourages outcome measurement to be
transparent and useful.
Why measure?
Measurement is fundamental to science. In medicine
measurement underpins most clinical decisions. The devel-
opment of disease diagnostic criteria, evaluation of change
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2006.A1in patients’ condition over time, and determining prognosis
are clinical processes that require some form of observation
and measurement either ad hoc or as part of a formal pro-
cedure. Measurement has often been antecedent to dis-
ease deﬁnition itself. The concept of the condition of
diabetes was obscure at best until we were able to measure
urinary and later blood glucose. Similarly, the deﬁnition of
osteoarthritis may in turn be modiﬁed to reﬂect our capacity
to measure articular cartilage dimensions.
What to measure?
What to measure depends on our intent. From our limited
knowledge of the pathobiology of osteoarthritis, we have lit-
tle a priori guidance here. Measurement content can reﬂect
anatomy: different joints, different tissues within each joint
(cartilage, bone, synovium, tendon, meniscus), and different
features of each tissue (e.g., cartilage thickness, volume,
stiffness, composition). Ultimately we are more interested
in how a patient feels, functions or survives rather than
anatomical measurement. Sometimes a distinction is made
between outcomes, such as symptoms, irreversible morbid
events and survival, whose importance is unquestioned,
and anatomical or laboratory outcomes that may be easy
to measure but their importance to the patient has not
been demonstrated. These outcomes may be substituted
for clinical outcomes and are called surrogate outcomes.
Although the use of surrogate outcomes in clinical trials
reduces sample size requirements and trial duration, they
can only be justiﬁed if there is strong evidence that thera-
peutic targeting of the surrogate will translate into a beneﬁ-
cial patient outcome.
How to measure?
Data can be qualitative or quantitative or a combination of
the two. Qualitative data can be described in all its aspects
but may not be easily measurable, for example, the consis-
tency (soft or ﬁrm) of a lump and/or quality (blowing or
harsh) of a cardiac murmur. Quantitative data can easily
be described using a dimensional scale. Often qualitative0
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Checklist for evaluating a measure
1. What is its purpose? How will it be used?
1.1 Is the purpose described in sufﬁcient detail?
1.2 Is the subject group deﬁned?
1.3 Are comparisons to be made?
1.4 If so, will these comparisons be on individuals, on groups or both?
1.5 If so, will these comparisons be concurrent, longitudinal or both?
1.6 If applied to individuals, was it standardized?
1.7 Are reference or normative values provided? How were they developed? Are they stratiﬁed by relevant cofactors?
2. Were all aspects described in sufﬁcient detail so that others can reproduce it?
Truth
3. Is it valid for your purpose?
3.1 Are all types of validity addressed?
3.1.1 Is it credible (face validity)?
3.1.2 Is it comprehensive (content validity)?
3.1.3 Does it agree (by independent and blind comparison) with other measures that reﬂect the same concept (construct validity)?
3.1.4 Does it agree (by independent and blind comparison) with a ‘gold standard’ (concurrent criterion validity)?
3.1.5 Does it predict (by independent and blind comparison) a future ‘gold standard’ (predictive criterion validity)?
3.2 Was the study design and analysis satisfactory?
3.2.1 Was an appropriate selection (and spectrum) of subjects studied? How were they selected? Was a control group included?
3.2.2 Was an independent and blind comparison performed for determination of construct and criterion validity?
3.2.3 Were the statistical methods adequately described and appropriately chosen?
 If both measures are continuous are intraclass correlation coefﬁcient (1.0 is perfect reliability agreement), 95% limits of agreement
(the smaller the better), and mean difference (i.e., paired t-test, and again the smaller the better) and mean vs difference or mean
vs variance plot (to examine important trends) reported?
 If both measures are categorical are the weighted and unweighted kappa (1.0 is perfect agreement), sensitivity, speciﬁcity and
likelihood ratio reported?
 If one measure is categorical and the other continuous is an ROC curve reported?
 If both measures are continuous but units are different are the units rescaled or standardized to allow reporting using the methods
described above or are correlation and linear regression methods of analysis reported?
3.2.4 Was the study large enough to draw conﬁdent conclusions?
Discrimination: reliability and responsiveness
4. Is it sufﬁciently reliable for your purpose?
4.1 Were all facets of reliability evaluated (between occasions, procedural, within observers, between observers, other sources of
variability)?
4.2 Was the study design and analysis satisfactory?
4.2.1 Did the subjects reﬂect the extremes of the spectrum where inconsistency is more common?
4.2.2 Was reliability tested independently and blind to previous results?
4.2.3 Were the statistical methods adequately described and appropriately chosen?
 If continuous measures, are the intraclass correlation coefﬁcient, limits of agreement (smallest detectable difference), and mean
difference (i.e., paired t-test), coefﬁcient of variation and mean vs difference or mean vs variance plot all reported?
 If categorical measures, were percentage agreement (weighted and unweighted) and kappa statistic (weighted and unweighted)
all reported?
4.2.4 Was the study large enough to draw conﬁdent conclusions?
5. Is it sufﬁciently responsive for your purpose?
5.1 Was more than one aspect of responsiveness evaluated (different time frames)?
5.2 Was the Study Design and Analysis satisfactory?
5.2.1 Did the subjects reﬂect the middle of the spectrum to optimize discrimination?
5.2.2 Was responsiveness tested independently and blind to previous results?
5.2.3 Were the statistical methods adequately described and appropriately chosen?
 Is the relative efﬁciency reported? This is the square of the ratio of two paired t statistics (or two paired z statistics). The square of
the paired t statistic is also known as the coefﬁcient of variation, so relative efﬁciency is also the ratio of the coefﬁcients of var-
iation. For within subject change, a large paired t statistic indicates good responsiveness.
 Is the ‘standardized response mean’ (SRM) reported? This is the mean change in scores from time zero to time one divided by the
standard deviation of these changes. A large SRM indicates good responsiveness.
 Is the smallest detectable difference reported. This is a measurement error based deﬁnition of responsiveness and is the absolute
value of the 95% conﬁdence limits around the standard deviation of the difference scores from a testeretest reliability study?
5.2.4 Was the study large enough to draw conﬁdent conclusions?
6. Are sub-components to be used separately?
6.1 If so, does each component meet ﬁlter components of validity, reliability and responsiveness?
Feasibility
7. Is it sufﬁciently feasible?
7.1 Are there procedural problems in administration?
7.2 Is training required?
7.3 Are standard instructions available? Are they clear?
7.4 Are reference or normative values provided? How were they developed? Are they stratiﬁed by relevant cofactors?
7.5 What are the costs?
7.6 Is it easily available?
7.7 What are the time issues?
7.8 Is it acceptable to all users?
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softening of arthroscopically probed articular cartilage,
therefore the distinction between the two may be subtle.
Levels of measurement have been deﬁned from the psy-
chosocial disciplines as nominal, ordinal, interval and ratio6.
The distinction is important because level of measurement
determines the statistical method required for analysis and
some statistical methods are more efﬁcient, therefore
more powerful than others. In medicine we are more familiar
with the level of measurement of variables being described
as discrete or continuous. We also use the terms categori-
cal, binary, dichotomous, graded and ranked variables.
How do they all compare? Nominal ‘naming’ variables are
categorical variables such as race, diseases, etc. They
have no intrinsic dimensional scale. Some categorical vari-
ables can take on only two values and these are called
dichotomous or binary variables. Gender is one example
of a non-directional binary variable. Responder or non-re-
sponder is an example of a directional binary variable. Nom-
inal, categorical, binary and dichotomous variables are all
discrete variables. Ordinal measures are equivalent to
ranked or graded measures. They take on more than two
values and have direction but sit uncomfortably between
categorical and continuous measures because the interval
between rankings or grades may not be equal. This has
implications regarding the statistical methods that should
be used to analyse ordinal variables and is the subject of
considerable debate. Interval variables are continuous
measures that have equal intervals (such as temperature)
and ratio variables are interval variables that have a true
zero point (such as height).
A look at the osteoarthritis imaging literature illustrates
the considerable choice available for the numerical process
of measurement. Clinical researchers new to the ﬁeld of
measurement must be aware of these alternatives. For
example, osteophytes can be (1) counted (discrete vari-
able); (2) graded on a scale of size or number or position
(ordinal or ranked variable); (3) we can combine (1) and
(2) to give a composite osteophyte score; (4) the dimen-
sions (such as height) of the osteophyte can be directly
measured in millimeters; or (5) measuring more than one
dimension to give total osteophyte area or volume. As
a general principle, one should avoid grading or simple
counts if one can use a dimensional measurement, as the
latter minimizes information loss. However, grading is often
quicker and the end result often agrees close enough to the
dimensional measurement, and may be more reliable.
Sometimes dimensional measurement is not technically
possible.
The methods used to construct a composite of different
kinds of measurements also differ7,8, the most common
being arithmetic such as in the Disease Activity Score9
and Boolean such as in the ACR2010 and the RA remission
criteria11. Other aspects are encountered in the develop-
ment and validation of a measure can either be driven by
expert opinion, be statistically driven with cross-sectional
data, or be explicitly, prospectively data-driven. The last of
the three is a type of predictive validity12. The studies that
evaluate the performance of new and existing measures
are often called method-comparison studies.
OMERACT ﬁlter
TheOMERACT process improves outcomemeasurement
in rheumatology because it is data-driven, iterative and
consensus building1. The OMERACT ﬁlter e truth,discrimination, feasibility e deﬁnes the essential compo-
nents of a measure. TRUTH is fundamental. Does it mea-
sure what is intended? Is the measure unbiased? Is the
measure relevant?13 Truth captures all aspects of validity:
face, content, construct, criterion (see Table I) terminology
derived from the psychosocial literature. Accuracy and pre-
cision, terms commonly used in the biomedical literature,
also capture truth, but they are not synonymous. For exam-
ple, in a method-comparison study of continuous measures,
to determine how well the measures agree we calculate the
difference between the two measurements for each subject.
Accuracy is themean of these differences whereas precision
is the standard deviation of the differences14. However, pre-
cision has also been used to describe the property of reliabil-
ity or consistency in medicine and this confusion in
terminology has caused problems both with the design of
method-comparison studies and their analysis. DISCRIMI-
NATION includes the related concepts of reliability (the
degree to which a result obtained by a measure can be rep-
licated15) and sensitivity to change, which is also known as
responsiveness or discriminant validity of a measure. All
else being equal, a measure that has poor reliability
(because of the random error) will also be less responsive.
The study design determines whether the objective is to
determine the stability of a measure (reliability) or its ability
to respond to external change (responsiveness). Reliability
should be reported using both relative and absolute statistics
because they provide different information and incorporate
certain biases depending on the study design and subjec-
ts16e18. Responsiveness can also be reported using several
methods19e21. FEASIBILITY is conceptually straightforward.
Can themeasure be applied easily, given constraints of time,
money, and interpretability? It can be divided into relevant
component parts such as personnel, time, costs, acceptabil-
ity, ethics, adverse events, and so forth. There are overlap-
ping aspects to this ﬁlter. The well-known tradeoff of truth
and feasibility applies across all measures.
The OMERACT ﬁlter summarizes key criteria of outcome
measurement. In Table I, I provide a users guide to mea-
surement in medicine. The checklist is a series of questions
that should be used when developing new measures or
when evaluating existing ones.
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